1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Wang, Y.
Henz, M.E.
Gallagher, N.L.F.
Chai, S.
Yan, L.Z.
Gibbs, A.C.
Stiles, M.E.
Wishart, D.S.
Vederas, J.C.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
38
15438
15447
10.1021/bi991351x
10569926
Solution structure of carnobacteriocin B2 and implications for structure-activity relationships among type IIa bacteriocins from lactic acid bacteria.
1999
10.2210/pdb1cw6/pdb
pdb_00001cw6
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
3937.323
TYPE IIA BACTERIOCIN LEUCOCIN A
LEUCOCIN A-UAL 187
1
nat
polymer
no
no
KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW
KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Leuconostoc
sample
1244
Leuconostoc gelidum
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
1999-09-08
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
2LEU CONTAINS THE SAME PEPTIDE WITH A STRUCTURE BASED ON FEWER CONTRAINTS.
RCSB
Y
RCSB
1999-08-25
REL
REL
THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES. THE
STRUCTURE WAS DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY.
STRUCTURES WITH ACCEPTABLE COVALENT GEOMETRY,STRUCTURES WITH FAVORABLE NON-
BOND ENERGY,STRUCTURES WITH THE LEAST RESTRAINT VIOLATIONS,STRUCTURES WITH THE
LOWEST ENERGY
18
18
2D NOESY
0
2.8
AMBIENT
298
K
THE REFINED STRUCTURES ARE BASED ON A TOTAL OF 434 INTERPROTON DISTANCE
RESTRAINTS, 27 3JHNHA COUPLING CONSTANT RESTRAINTS, AND 136 PROTON CHEMICAL
SHIFT RESTRAINTS
simulated annealing
9
closest to the average
2MM LEUCOCIN A IN 90% TFE-D3,10% H2O
BRUNGER
structure solution
X-PLOR
3.85
VRIAN
processing
VNMR
5.1
BRUNGER
refinement
X-PLOR
3.85
500
Varian
UNITY
LYS
1
n
1
LYS
1
A
TYR
2
n
2
TYR
2
A
TYR
3
n
3
TYR
3
A
GLY
4
n
4
GLY
4
A
ASN
5
n
5
ASN
5
A
GLY
6
n
6
GLY
6
A
VAL
7
n
7
VAL
7
A
HIS
8
n
8
HIS
8
A
CYS
9
n
9
CYS
9
A
THR
10
n
10
THR
10
A
LYS
11
n
11
LYS
11
A
SER
12
n
12
SER
12
A
GLY
13
n
13
GLY
13
A
CYS
14
n
14
CYS
14
A
SER
15
n
15
SER
15
A
VAL
16
n
16
VAL
16
A
ASN
17
n
17
ASN
17
A
TRP
18
n
18
TRP
18
A
GLY
19
n
19
GLY
19
A
GLU
20
n
20
GLU
20
A
ALA
21
n
21
ALA
21
A
PHE
22
n
22
PHE
22
A
SER
23
n
23
SER
23
A
ALA
24
n
24
ALA
24
A
GLY
25
n
25
GLY
25
A
VAL
26
n
26
VAL
26
A
HIS
27
n
27
HIS
27
A
ARG
28
n
28
ARG
28
A
LEU
29
n
29
LEU
29
A
ALA
30
n
30
ALA
30
A
ASN
31
n
31
ASN
31
A
GLY
32
n
32
GLY
32
A
GLY
33
n
33
GLY
33
A
ASN
34
n
34
ASN
34
A
GLY
35
n
35
GLY
35
A
PHE
36
n
36
PHE
36
A
TRP
37
n
37
TRP
37
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
THR
10
A
N
THR
10
A
O
GLY
13
A
O
GLY
13
1
A
A
O
H
TRP
PHE
18
22
1.47
2
A
A
O
H
TRP
PHE
18
22
1.56
2
A
A
O
H
HIS
SER
8
15
1.59
2
A
A
O
N
THR
SER
10
12
2.17
3
A
A
O
H
TRP
PHE
18
22
1.54
3
A
A
O
H
HIS
SER
8
15
1.59
4
A
A
O
H
HIS
SER
8
15
1.37
4
A
A
O
H
TRP
PHE
18
22
1.40
5
A
A
O
H
TRP
PHE
18
22
1.43
5
A
A
O
H
HIS
SER
8
15
1.49
6
A
A
O
H
TRP
PHE
18
22
1.49
7
A
A
O
H
TRP
PHE
18
22
1.46
7
A
A
O
H
HIS
SER
8
15
1.56
8
A
A
O
H
TRP
PHE
18
22
1.53
8
A
A
O
H
HIS
SER
8
15
1.53
9
A
A
O
H
TRP
PHE
18
22
1.50
10
A
A
O
H
TRP
PHE
18
22
1.50
10
A
A
O
H
HIS
SER
8
15
1.50
11
A
A
O
H
TRP
PHE
18
22
1.49
11
A
A
O
H
HIS
SER
8
15
1.59
12
A
A
O
H
TRP
PHE
18
22
1.41
13
A
A
O
H
TRP
PHE
18
22
1.52
14
A
A
O
H
TRP
PHE
18
22
1.39
15
A
A
O
H
TRP
PHE
18
22
1.50
16
A
A
O
H
TRP
PHE
18
22
1.45
16
A
A
O
H
HIS
SER
8
15
1.56
17
A
A
O
H
TRP
PHE
18
22
1.56
17
A
A
O
H
THR
SER
10
12
1.57
17
A
A
O
H
HIS
SER
8
15
1.59
17
A
A
O
N
THR
SER
10
12
2.08
18
A
A
O
H
TRP
PHE
18
22
1.40
18
A
A
O
H
HIS
SER
8
15
1.57
1
A
TYR
3
-109.73
40.34
1
A
ASN
5
-145.80
52.42
1
A
LYS
11
36.10
34.77
1
A
SER
12
74.04
47.00
1
A
TRP
18
64.07
-65.14
1
A
ASN
34
66.11
-61.12
1
A
PHE
36
55.64
80.77
2
A
TYR
3
-103.26
41.17
2
A
ASN
5
-148.14
39.69
2
A
LYS
11
22.55
-61.46
2
A
TRP
18
65.55
-70.49
3
A
LYS
11
77.73
-84.27
3
A
SER
12
-153.44
22.68
3
A
TRP
18
65.90
-60.71
3
A
PHE
36
72.29
-155.83
4
A
ASN
5
-148.01
38.94
4
A
CYS
9
-119.39
78.21
4
A
LYS
11
83.21
-89.68
4
A
SER
12
-149.61
20.79
4
A
TRP
18
17.21
-64.93
4
A
PHE
36
77.42
112.22
5
A
ASN
5
-146.98
33.25
5
A
LYS
11
87.57
-85.38
5
A
SER
12
-150.49
31.89
5
A
TRP
18
19.51
-69.02
5
A
ASN
34
-150.93
-46.86
5
A
PHE
36
-162.21
35.43
6
A
TYR
3
-105.77
42.20
6
A
ASN
5
-146.47
29.66
6
A
TRP
18
70.17
-59.47
7
A
ASN
5
-107.55
50.71
7
A
CYS
9
-114.16
79.21
7
A
LYS
11
83.05
-87.26
7
A
SER
12
-150.92
22.63
7
A
TRP
18
64.94
-63.25
7
A
ASN
34
-152.22
46.15
8
A
TYR
3
-106.06
40.53
8
A
ASN
5
-147.91
48.17
8
A
CYS
9
-113.23
65.24
8
A
LYS
11
29.11
101.32
8
A
SER
12
82.02
-46.48
8
A
TRP
18
62.41
-63.43
9
A
ASN
5
-146.48
45.95
9
A
TRP
18
66.31
-64.94
9
A
PHE
36
-163.12
45.39
10
A
ASN
5
-146.48
33.57
10
A
LYS
11
92.42
-85.88
10
A
SER
12
-151.44
26.50
10
A
TRP
18
68.26
-63.92
10
A
PHE
36
76.59
-1.11
11
A
ASN
5
-148.89
48.14
11
A
LYS
11
47.08
-66.42
11
A
SER
12
-154.59
17.08
11
A
TRP
18
66.24
-69.58
12
A
ASN
5
-148.11
47.48
12
A
TRP
18
66.96
-62.61
12
A
ASN
34
-98.14
-68.43
13
A
TYR
3
-132.55
-31.71
13
A
ASN
5
-101.34
49.97
13
A
TRP
18
68.63
-60.82
13
A
PHE
36
-161.69
117.59
14
A
ASN
5
-146.36
49.21
14
A
CYS
9
-106.99
75.97
14
A
LYS
11
85.59
-87.96
14
A
SER
12
-152.06
21.80
14
A
TRP
18
68.16
-62.54
14
A
ALA
30
-79.31
-78.66
14
A
ASN
31
43.96
71.60
14
A
PHE
36
-161.94
33.61
15
A
ASN
5
-145.54
40.83
15
A
TRP
18
65.47
-64.85
16
A
ASN
5
-147.06
32.18
16
A
CYS
9
-116.09
77.81
16
A
LYS
11
39.40
35.04
16
A
SER
12
73.39
33.02
16
A
TRP
18
68.26
-66.27
16
A
ASN
34
-152.06
-42.37
16
A
PHE
36
-161.06
70.87
17
A
ASN
5
-146.82
36.61
17
A
LYS
11
25.08
-54.44
17
A
TRP
18
67.82
-59.73
17
A
ASN
34
45.33
76.95
17
A
PHE
36
-163.31
-78.85
18
A
ASN
5
-145.22
33.99
18
A
CYS
9
-106.11
78.10
18
A
LYS
11
37.27
-85.09
18
A
SER
12
-149.30
21.31
18
A
TRP
18
74.86
-68.92
18
A
ASN
34
53.74
95.76
18
A
PHE
36
50.67
173.56
REFINED SOLUTION STRUCTURE OF LEUCOCIN A
1
N
N
A
TRP
18
A
TRP
18
HELX_P
A
ALA
30
A
ALA
30
1
1
13
disulf
2.030
A
CYS
9
A
SG
CYS
9
1_555
A
CYS
14
A
SG
CYS
14
1_555
TOXIN
ANTIMICROBIAL PEPTIDE, BACTERIOCIN, TOXIN
LCCA_LEUGE
UNP
1
P34034
25
61
1CW6
1
37
P34034
A
1
1
37
2
anti-parallel
A
HIS
8
A
HIS
8
A
THR
10
A
THR
10
A
GLY
13
A
GLY
13
A
SER
15
A
SER
15
1
P 1